Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.167 | Single-center, randomized, double-blind, placebo-controlled, single-dose and multiple-dose, parallel-group study to investigate pharmacokinetics, pharmacodynamics, safety and tolerability of vericiguat in Chinese healthy male subjects under fed condition |
Dr. LUK Andrea On Yan 陸安欣 |
| 2015.208 | Using C-peptide, anti-glutamic acid decarboxylase antibodies and body mass index to identify patients with young-onset type 2 diabetes for early insulin therapy | Dr. LUK Andrea On Yan |
| 2014.056 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY WITH A 78-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY | Dr. LUK Andrea On Yan |
| 2016.046 | Interactive effects of testosterone, estradiol and CAG repeat polymorphism of androgen receptor gene on cardiovascular-renal diseases and mortality in men with type 2 diabetes |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.248 | A different level of single-dose and multiple-dose study to evaluate the pharmacokinetics of ranolazine in a Chinese population |
Dr. LUK Andrea On Yan 陸安欣 |
| 2015.540 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Prof. LUK Andrea On Yan 陸安欣 |
| 2014.699 | Dose-response study of gevokizumab (S 78989 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, parallel-group, placebo controlled, study. | Dr. LUK Andrea On Yan |
| 2017.451 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7020531 AND METABOLITES FOLLOWING ORAL ADMINISTRATION TO CHINESE HEALTHY VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2012.482 | Descriptive study of clinical profile of Hong Kong diabetic population | Dr Luk Andrea On Yan |
| 2026.588 | A Phase I, Single Dose, Dose-ascending, Pharmacokinetic Study of Semaglutide Nasal Spray (PT002) in Healthy Volunteers | Prof. Luk Andrea On Yan |
| 2026.276 | Population-based target trial emulation to examine the skeletal effects of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes |
Prof. LUK Andrea On Yan 陸安欣 |
| 2020.438 | Delineating the metabolic architecture and response to anti-hyperglycaemic drug treatment in lean type 2 diabetes in Chinese | Dr. LUK Andrea On Yan |
| 2020.032 | Health and Economic Impacts of Pre-Diabetes, Gestational Diabetes, Type 1 and Type 2 Diabetes in Hong Kong |
Dr. LUK Andrea On Yan 陸安欣 |
| 2018.093 | A different level of single-dose and multiple-dose study to evaluate the pharmacokinetics of Bilastine in a Chinese population |
Dr. LUK Andrea On Yan 陸安欣 |
| 2018.232 | Search for Maturity-Onset Diabetes of the Young in Chinese with Young-Onset Diabetes | Dr. LUK Andrea On Yan |
| 2020.132 | A Trial Investigating the Pharmacokinetic Properties of Fast-acting Insulin Aspart in Chinese Subjects with Type 1 Diabetes or Type 2 Diabetes |
Dr. LUK Andrea On Yan 陸安欣 |
| 2025.869 | Detection of renin-independent aldosteronism in Chinese individuals with early-onset hypertension and type 2 diabetes |
Prof. Luk Andrea On Yan 陸安欣 |
| 2024.466 | A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants with Dyslipidaemia | Prof. LUK Andrea On Yan |
| 2025.145 | Unravelling the pathogenicity of genetic variants in Wolfram Syndrome 1 gene in Chinese with young-onset diabetes |
Prof. LUK Andrea On Yan Andrea On Yan Luk |
| 2024.159 | Implementation of a novel diabetes prevention programme in Hong Kong Chinese workforce at high risk of type 2 diabetes | Prof. LUK Andrea On Yan |
| 2022.404 | Healthcare utilisation and diseases in people with and those without diabetes in Hong Kong before and after COVID-19 pandemic | Prof. Luk Andrea On Yan |
| 2020.689 | ReFineDR: Observational study of Routine ophthalmological examinations of patients included in the 2 Bayer sponsored phase 3 clinical trials FIDELIO and FIGARO to investigate the effect of Finerenone on delaying the progression of Diabetic Retinopathy |
Dr. LUK Andrea On Yan 陸安欣醫生 |
| 2022.148 | A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants with Mild to Moderate COVID-19 |
Dr. LUK Andrea On Yan 陸安欣 |
| 2021.501 | An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (BIIB098) in Chinese and Caucasian Adult Healthy Participants |
Dr. LUK Andrea On Yan 陸安欣 |
| 2022.634 | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus |
Prof. LUK Andrea On Yan 陸安欣 |
| 2023.369 | Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Prof. LUK Andrea On Yan |
| 2023.314 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION | Prof. LUK Andrea On Yan |
| 2021.164 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with diabetic kidney disease. | Dr. LUK Andrea On Yan |
| 2013.071 | A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia | Dr. LUK Andrea On Yan |
| 2011.418 | A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab (AMG 145) | Dr. LUK Andrea On Yan |
| 2012.489 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2013.070 | A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 | Dr. LUK Andrea On Yan |
| 2011.182 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2011.084 | A randomized controlled study to evaluate the effect of n-3 polyunsaturated fatty acids on the progression of diabetic kidney disease | Dr. Luk Andrea On Yan |
| 2013.588 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE, THE VERTIS CV STUDY | Dr. LUK Andrea On Yan |
| 2014.441 | A MULTICENTRE RANDOMIZED PROGRAM BY USING A DIABETIC KIDNEY DISEASE (DKD) REGISTRY TO TREAT TO MULTIPLE TARGETS (TMT) (DKD-TMT) | Dr. LUK Andrea |
| 2015.487 | Retinopathy of Prematurity: Applicability and Compliance of Screening Guidelines in Hong Kong | Dr. LUK Abbie Sheung Wan |
| 2014.016 | Surgical Outcome of Medial Rectus Resection for Recurrent Exotropia | Dr. LUK Abbie |
| 2008.365 | Validation Study of Assessment of Capacity for Everday Decision-Making for Chinese Elderly | Dr Lui Wing Cheong |
| 2008.196 | Biological Implication of Elefated Serum Hepatocyte Growth Factor (HGF) in the Progressionof Nasopharyngeal Carcinoma (NPC) | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2008.195 | High-Content Screening (HCS) Platform for Molecular Drug Testing, Therapeutic Target Identification and Mechanistic Signaling Studies in Asian Prevalent Cancers | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2008.022 | Oncogenic Dependency on Receptor Tyrosine Kinase (RTK): Implication for Molecular Targeting in Nasopharyngeal Carcinoma (NPC) | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2011.612 | Comparison of satisfaction with communication during general outpatient consultation of doctors and patients | Ms Lui Wai Yan |
| 2010.081 | Oncogenic Regulation of TIGAR by STAT3: A Mechanistic Study | Ph.D. LUI Vivian Wai Yan |
| 2017.293 | ALK/PIK3CA Genetic Coupling: Implications for Progression and Personalized Therapy in Head and Neck Cancer |
Dr. LUI Vivian Wai Yan 呂偉欣 |
| 2017.145 | RAC1 Genomic Alterations Drive Head and Neck Cancer Progression |
Dr. LUI Vivian Wai Yan 呂偉欣 |
| 2009.369 | Determinants and barriers for help seeking in persons with self-harm and aggressive ideations | Dr. Lui Victor Wing Cheong |
| 2011.282 | EFFECTIVENESS OF TOE SPREADER & DYNAMIC HALLUX VALGUS STRAP ON FOOT FUNCTION FOR JUVENILE HALLUX VALGUS - PROSPECTIVE, CROSSOVER RANDOMIZED CONTROL TRIAL | Dr. Lui Tun Hing |
| 2025.139 | Epidemiology of fusariosis in NTEC | Dr. LUI Tin Long |
| 2009.282 | Socio-demographic Risk Factors for adolescent Sports Injury in Hong Kong: A Pilot Study | Ms. Lui Tai Wah |
Page 115 of 289.